New biotech sector master plan: 20,000 new jobs and a boost for Dutch GDP

Fr 12 December 2025

Targeted investments in red biotechnology will lead to a structural GDP boost of 1.2 percentage points, 20,000 additional high-quality jobs, and faster access to innovations for patients. This is evident from an economic analysis by KPMG. This allows red biotechnology – innovative medicines, vaccines, diagnostics, and advanced therapies – to become a cornerstone of the Netherlands as a whole. The analysis was prepared in the context of Peter Wennink's national investment agenda presented today.

National ambitions

KPMG demonstrates that targeted investments in Biotech Nexus – the national program proposed by the biotech sector – have significant economic leverage: every euro invested in public funds leads to an average of €2.50 in private investment and almost €2 in additional economic activity. Biotech Nexus coordinates and allocates public funds based on transparent criteria. It aims to unite regional strengths, accelerate knowledge valorization, and support companies in scaling up. This also enables the Dutch biotech ecosystem to take on an international leadership role.

National engine

"This initiative will serve as our national engine for red biotechnology," says Annemiek Verkamman, director of Hollandbio. "It will stimulate the growth and continued development of young companies by improving access to growth capital, strengthening the professional application of scientific knowledge, and supporting young companies with experienced entrepreneurs and investors." Furthermore, in its own growth strategy – compiled in a report – the sector proposes three illustrative national projects that contribute to business growth, attracting capital, and the development of new therapies, diagnostics, and solutions for the treatment of infectious diseases.

"Targeted investments in red biotech not only offer opportunities for the pharmaceutical sector but also strengthen the manufacturing industry, sustainability, and our social agenda."

Peter Ketelaar Chairman LIFE Cooperative

Fewer regulations, more data, faster access

The Netherlands boasts strong clusters, high-quality infrastructure, and internationally recognized knowledge institutions. To fully utilize the biosector's growth potential, strengthened preconditions are needed. These include access to capital and talent, shared and secure access to (bio)data, predictable and efficient permitting procedures, clinical research, rapid market access for innovations, and sufficient physical space for research, scaling, and production.

Peter Ketelaar, voorzitter LIFE Cooperative

Peter Ketelaar, voorzitter LIFE Cooperative

Strategic autonomy

Peter Ketelaar (Board, LIFE Cooperative):
“Targeted investments in red biotech not only create opportunities for the pharmaceutical sector, but also strengthen manufacturing, sustainability, and our broader societal agenda. It’s about strategic autonomy: the Netherlands must be able to produce essential medicines itself.”

Wiro Niessen (Executive Board, UMCG):
“The strength of the Netherlands lies in the collaboration between its regional hotspots, strong biobanks such as Lifelines, the expertise of university medical centers, and facilities like the Dutch AI Factory in Groningen. By linking reliable data and expertise to the innovative power of companies in our biotech sector, we create an innovation ecosystem that will significantly boost economic activity and exports — enabling biotech to become one of the cornerstones of the Dutch economy.”

Edward van der Meer (Director, Campus Groningen, and Chair, NCO – National Campus Council):
“For the campuses of national importance, this masterplan brings concrete new opportunities for research, education, and collaboration with industry. Students and researchers can contribute to groundbreaking innovations while gaining experience in an ecosystem focused on sustainable and strategically important biotechnology.”

Wiro Niessen, Raad van Bestuur UMCG

Wiro Niessen, Raad van Bestuur UMCG

Maybe also interesting for you

Th 12 March 2026

“Every euro raised goes directly to the children.”

Op zondag 31 mei 2026 staat Groningen in het teken van sport, doorzettingsvermogen en betrokkenheid. Tussen alle lopers is ook het herkenbare roze van Vrienden Beatrix Kinderziekenhuis zichtbaar.

Mo 23 February 2026

Groningen hosts the Dutch Medicines Winter Afternoon full of innovation

The LIFE Cooperative, part of the Northern Netherlands life sciences ecosystem at Campus Groningen, is organizing the Dutch Medicines Winter Afternoon together with FIGON on Thursday, 26 February. This fully booked event brings together leading scientists and industry experts to explore the latest developments in innovative medicines and advanced drug delivery. Read the full article as published by the LIFE Cooperative.National Attention for Sold-Out Dutch Medicines Winter Afternoon: Innovative Medicines and Advanced Drug Delivery Take Center Stage in Groningen Innovation in medicines takes center stage on Thursday, 26 February during the Dutch Medicines Winter Afternoon, an inspiring event organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with the LIFE Cooperative. “We are extremely proud of the strong line-up at this event, bringing together leading experts from science and industry to explore the frontiers of drug development. The fact that registrations are already fully booked underlines the great importance of this event for the life sciences ecosystem, and in particular for the Northern Netherlands,” says Ronald Hesse, Director of the LIFE Cooperative. The Dutch Medicines Winter Afternoon brings together scientists, innovators, and professionals from across the Netherlands for an afternoon of insights, knowledge exchange, and networking opportunities. The speaker line-up features experts from both academia and industry. This event is already fully booked. Interested in joining the waiting list? Please email: amber@lifecooperative.nlConnecting force The afternoon will be opened by Prof. Klaas Poelstra of the University of Groningen (RUG), Chair of FIGON, who will outline the importance of innovative drug development in the Netherlands. This will be followed by an introduction by Robert Hof on behalf of the LIFE Cooperative, highlighting the cooperative’s role as a connecting force within the regional ecosystem. The first session block before the break focuses on innovation in drug delivery systems. Rob Steendam (CTO, InnoCore) will discuss the development of long-acting SynBiosys® microspheres for controlled and sustained drug release. Jaap Wieling (CEO, PureIMS) will present the potential of dry-powder inhalation via the Cyclops® technology for both pulmonary and systemic indications. From an academic perspective, Prof. Marleen Kamperman (University of Groningen) will explore the potential of polyelectrolyte coacervates as innovative drug delivery platforms.Deep dive After the break, the focus shifts to advanced nanomedicines and clinical development strategies. Dr. Flávia Sousa (RUG) will present her work on polymer-based nanomedicines for the delivery of biotherapeutics to the brain. Dr. Ad Roffel (ICON plc, Groningen) will address mass balance and absolute bioavailability studies with ¹⁴C-labeled drugs in humans, an essential component of clinical drug development. Prof. Erik Frijlink (RUG) will reflect on the value of innovation within both established and advanced drug delivery systems, placing technological progress in a broader pharmaceutical context. Finally, Prof. Helder Santos (RUG) will demonstrate how nanomedicines are being used for RNA delivery in myocardial infarction repair, a promising development in cardiovascular therapy. “We are extremely proud of the strong line-up at this event, bringing together leading experts from science and industry to explore the frontiers of drug development. The fact that registrations are already fully booked underlines the great importance of this event for the life sciences ecosystem, and in particular for the Northern Netherlands." - Ronald Hesse, director LIFE CooperativeClosing and networking The afternoon will conclude with a contribution by Peter Ketelaar (LIFE Cooperative), followed by closing remarks from Prof. Klaas Poelstra. Participants will then have the opportunity to connect and continue discussions during the networking reception. Hesse looks forward to the event: “With this event, FIGON and the LIFE Cooperative underline the strength of collaboration between academia, industry, and clinical practice. The Dutch Medicines Winter Afternoon promises not only to be an inspiring afternoon, but also to provide momentum for further innovation and collaboration within the Northern Netherlands life sciences ecosystem.” Text: lifecooperative.nlPhotographer: Casper Maas

Th 19 February 2026

New Master Plan for the Healthy Ageing Campus Officially Approved

The master plan for the Healthy Ageing Campus has officially been approved! This marks an important step in developing the campus as a hub for knowledge, innovation, and collaboration. With a focus on greenery, health, and connection to the city, the campus will become a vibrant environment where research, education, healthcare, and business come together. The vision provides space for new laboratories, building renovations, meeting places, and closer collaboration between UMCG, RUG, and the business community. Read the whole article by the UMCG below.Green light for the Healthy Ageing Campus Master Plan On Wednesday, 18 February 2026, the Groningen City Council formally approved the master plan for the Healthy Ageing Campus. This is a major milestone, as the plan provides the framework for the campus’s further development and its integration with the surrounding area. At the end of last year, the University of Groningen (RUG), the University Medical Center Groningen (UMCG), and the City of Groningen presented an ambitious, future-proof plan for the campus. Shared ambitions have been translated into coherent spatial and programmatic guidelines for current and future developments. In other words: how much space is available for which functions on the campus, and where is the most suitable location for them? The renewed campus will: Provide space for knowledge, innovation, and collaboration, encouraging interaction between disciplines and people; Connect with the city, making the campus a natural part of Groningen life; Be a healthy and sustainable environment, with attention to greenery, physical activity, wellbeing, and a living environment that supports health; Be lively and accessible, bringing together living, working, research, studying, and healthcare.Next steps The master plan is not only a blueprint for the future, but also a concrete step toward further developing the current campus. Construction and renovation on the UMCG and RUG grounds are ongoing, and each project must now be assessed to determine what is possible. With the approval of this master plan, the way is cleared for follow-up decisions, including applying for demolition and building permits and further project development within the area. Upcoming projects include: The construction of the Central Laboratory for Diagnostics and Research (CLDR): a new laboratory building on the site of the former UCP building. This building will bring together various laboratories in one location to improve collaboration. Relocating laboratories from the Central Medical Complex is also necessary for the renovation and expansion of several hospital departments; Renovation and future-proofing of existing UMCG and RUG buildings, with attention to sustainability, flexibility, and integration with the heating/cooling system; Making the campus greener and more accessible, creating new meeting places and better connections to surrounding public spaces; Creating space for campus-related business activities, strengthening collaboration between UMCG, RUG, and the private sector.Municipality explores the future of DOT Initially, the master plan covered the area between Petrus Campersingel and Oostersingel, from Hanzeplein to the Oosterhamrikkanaal. In the newly approved plan, the Bodenterrein site has been separated, as the municipality is investigating the costs of possibly preserving DOT. More information on this will be available later this year. Read more about the Master Plan.Source text and pictures: umcg.nl